Syros Pharmaceuticals (SYRS) Competitors $0.03 +0.00 (+2.03%) As of 07/3/2025 12:37 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYRS vs. APVO, PCSA, ALZN, CDT, SCNI, PWUP, PTIX, SLRX, AKAN, and GRTXShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Aptevo Therapeutics (APVO), Heatwurx (PCSA), Alzamend Neuro (ALZN), Conduit Pharmaceuticals (CDT), Scinai Immunotherapeutics (SCNI), PowerUp Acquisition (PWUP), Atrinsic (PTIX), Salarius Pharmaceuticals (SLRX), Akanda (AKAN), and Galera Therapeutics (GRTX). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Its Competitors Aptevo Therapeutics Heatwurx Alzamend Neuro Conduit Pharmaceuticals Scinai Immunotherapeutics PowerUp Acquisition Atrinsic Salarius Pharmaceuticals Akanda Galera Therapeutics Aptevo Therapeutics (NASDAQ:APVO) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Which has more volatility and risk, APVO or SYRS? Aptevo Therapeutics has a beta of 5.58, indicating that its share price is 458% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Do insiders and institutionals have more ownership in APVO or SYRS? 8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 0.0% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor APVO or SYRS? In the previous week, Aptevo Therapeutics had 2 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 3 mentions for Aptevo Therapeutics and 1 mentions for Syros Pharmaceuticals. Aptevo Therapeutics' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syros Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is APVO or SYRS more profitable? Aptevo Therapeutics' return on equity of -779.42% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -779.42% -175.59% Syros Pharmaceuticals N/A -3,369.56%-97.04% Do analysts recommend APVO or SYRS? Aptevo Therapeutics presently has a consensus price target of $219,040.00, indicating a potential upside of 7,252,880.13%. Syros Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 13,180.21%. Given Aptevo Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aptevo Therapeutics is more favorable than Syros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has higher earnings and valuation, APVO or SYRS? Aptevo Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo Therapeutics$3.11M0.74-$24.13MN/AN/ASyros Pharmaceuticals$386K1.74-$164.57M-$3.03-0.01 SummaryAptevo Therapeutics beats Syros Pharmaceuticals on 7 of the 11 factors compared between the two stocks. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$673K$790.73M$5.54B$9.05BDividend YieldN/A4.84%5.24%4.02%P/E Ratio-0.011.3527.4320.23Price / Sales1.74226.97422.11118.64Price / CashN/A23.4436.8958.07Price / Book0.036.298.045.67Net Income-$164.57M-$27.73M$3.18B$249.13M7 Day PerformanceN/A1.82%2.89%3.28%1 Month PerformanceN/A9.90%3.70%5.56%1 Year PerformanceN/A10.79%36.15%21.12% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.3589 of 5 stars$0.03+2.0%$3.33+13,180.2%-99.5%$673K$386K-0.01120Gap DownAPVOAptevo Therapeutics2.1416 of 5 stars$3.05-1.0%$219,040.00+7,181,539.3%-100.0%$2.33M$3.11M0.0050PCSAHeatwurx3.6704 of 5 stars$0.21+4.5%$2.00+875.6%-89.3%$2.33MN/A0.0020News CoverageAnalyst RevisionGap UpALZNAlzamend Neuro2.6155 of 5 stars$2.91+0.3%$180.00+6,085.6%-91.6%$2.32MN/A0.004CDTConduit Pharmaceuticals0.0387 of 5 stars$2.76-4.2%N/A-99.7%$2.30MN/A0.003News CoverageHigh Trading VolumeSCNIScinai ImmunotherapeuticsN/A$2.28flatN/A-29.6%$2.28M$660K0.0020Positive NewsGap UpPWUPPowerUp AcquisitionN/A$0.28-7.0%N/AN/A$2.21MN/A0.00N/AGap DownHigh Trading VolumePTIXAtrinsic0.5632 of 5 stars$3.65-1.4%N/A-67.7%$2.18MN/A0.002Gap UpSLRXSalarius Pharmaceuticals0.7319 of 5 stars$0.90-9.5%N/A-63.2%$2.11MN/A0.0020Positive NewsAKANAkanda0.5651 of 5 stars$1.40-3.4%N/A-69.9%$2.07M$840K0.00110News CoveragePositive NewsGRTXGalera Therapeutics0.2859 of 5 stars$0.03-4.6%N/A-78.7%$2.05MN/A-0.0830 Related Companies and Tools Related Companies APVO Alternatives PCSA Alternatives ALZN Alternatives CDT Alternatives SCNI Alternatives PWUP Alternatives PTIX Alternatives SLRX Alternatives AKAN Alternatives GRTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
